{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:51:20Z","timestamp":1792741880246,"version":"4.5.0"},"reference-count":59,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Vet Comparative Oncology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Urothelial carcinoma (UC) is the most common tumour of the canine urinary bladder. Recently, BRAF mutation testing emerged as a diagnostic option, but its prognostic significance is unknown. This study investigates the relationship between BRAF (variant V595E) mutation status and overall survival in UC\u2010bearing dogs. Seventy\u2010nine patients histologically diagnosed with UC of the bladder and\/or urethra between 2006 and 2019 were included in this retrospective single\u2010centre\u2010study. Treatment consisted of meloxicam (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u200939, group 1 \u2018Melox\u2019), mitoxantrone and meloxicam (+\/\u2212 followed by metronomic chlorambucil;\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u200923, group 2 \u2018Chemo\u2019) or partial cystectomy followed by meloxicam +\/\u2212 mitoxantrone (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u200917, group 3 \u2018Sx\u2019). Survival was significantly influenced by treatment (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u2009.0002) and tumour location (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u2009.001) in both uni\u2010 and multivariable analyses. BRAF mutation was identified in 51 tumours (=64.6%) and had no statistically significant influence on overall survival: MST for BRAF\u2010negative patients 359 versus 214\u2009days for BRAF\u2010positive dogs (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u2009.055). However, in BRAF\u2010positive dogs, survival depended significantly on type of treatment in univariable analysis: MSTs for groups 1\u20133 were 151, 244 and 853\u2009days, respectively (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u2009.006); In BRAF\u2010positive group 2 (\u2018Chemo\u2019)\u2010patients, adjuvant metronomic chlorambucil after mitoxantrone more than doubled MST compared to patients receiving mitoxantrone alone (588 vs. 216\u2009days;\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u2009.030). In contrast, MSTs were not significantly different in BRAF\u2010negative patients among the three treatment groups (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u2009.069). Multivariate analysis of these data was not possible due to group size limitations. This study identified tumour location and treatment type, but not BRAF mutation status, as independent prognostic factors for overall survival.\n                  <\/jats:p>","DOI":"10.1111\/vco.12790","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T10:32:27Z","timestamp":1638959547000},"page":"449-457","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["<scp>BRAF<\/scp>\n                    mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006\u20132019)"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7435-8844","authenticated-orcid":false,"given":"Julia","family":"Gedon","sequence":"first","affiliation":[{"name":"Small Animal Clinic Hofheim  Hofheim am Taunus Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kehl","sequence":"additional","affiliation":[{"name":"Laboklin GmbH &amp; Co. KG  Bad Kissingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Aupperle\u2010Lellbach","sequence":"additional","affiliation":[{"name":"Laboklin GmbH &amp; Co. KG  Bad Kissingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf","family":"von Bomhard","sequence":"additional","affiliation":[{"name":"Veterinary Specialty Practice for Pathology  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarno M.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Small Animal Clinic Hofheim  Hofheim am Taunus Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2015.01.017"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12286"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ilar\/ilu018"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1740-8261.2002.tb00443.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1024\/0036-7281.149.7.314"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.239.3.350"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsap.12709"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.399"},{"issue":"6","key":"e_1_2_8_10_1","first-page":"1557","article-title":"Differential effects of MAPKs signaling on the growth of invasive bladder cancer cells","volume":"34","author":"Kumar B","year":"2009","journal-title":"Int J Oncol."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210421"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129534"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/vetsci6010031"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-14-0689"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144170"},{"issue":"5","key":"e_1_2_8_16_1","first-page":"289","article-title":"Diagnostic value of the BRAF variant V595E in urine samples, smears and biopsies from canine transitional cell carcinoma","volume":"46","author":"Aupperle\u2010Lellbach H","year":"2018","journal-title":"Tierarztl Prax Ausg K Kleintiere Heimtiere."},{"issue":"12","key":"e_1_2_8_17_1","first-page":"680","article-title":"First clinical studies on survival rate of dogs with transitional cell carcinoma and BRAF mutation V595E","volume":"64","author":"Pantke PD C","year":"2019","journal-title":"Kleintierpraxis."},{"issue":"5","key":"e_1_2_8_18_1","first-page":"313","article-title":"Detection of BRAF mutation in canine prostatic diseases","volume":"47","author":"Grassinger JM","year":"2019","journal-title":"Tierarztl Prax Ausg K Kleintiere Heimtiere."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.119.115808"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq258"},{"issue":"6","key":"e_1_2_8_21_1","first-page":"919","article-title":"BRAF V600E mutation and TERT promoter mutation in papillary thyroid carcinomas and their association with clinicopathological characteristics","volume":"50","author":"Yang T","year":"2019","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban."},{"issue":"1","key":"e_1_2_8_22_1","first-page":"30","article-title":"The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer","volume":"17","author":"Celik M","year":"2020","journal-title":"Med Glas (Zenica)."},{"key":"e_1_2_8_23_1","volume-title":"Tumors in Domestic Animals","author":"Meuten DJ","year":"2017"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-016-0882-6"},{"key":"e_1_2_8_25_1","unstructured":"HelmJR NicholsonI MorrisJ NasirL KnottenbeltCM.A preliminary study into the effects of meloxicam and Piroxicam on telomerase activity in canine transitional cell carcinoma. In:51st British Small Animal Veterinary Congress (BSAVA) edn. Birmingham (UK);2008."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.2000.61.478"},{"issue":"6","key":"e_1_2_8_27_1","first-page":"931","article-title":"Palliative intralesional interleukin\u20102 treatment in dogs with urinary bladder and urethral carcinomas","volume":"26","author":"Konietschke U","year":"2012","journal-title":"In Vivo."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.12533"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.242.11.1534"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2005.11.063"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.5326\/JAAHA-MS-6905"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1078-1439(99)00006-X"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2003.tb02424.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2246"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-150044"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1994.tb03232.x"},{"issue":"2","key":"e_1_2_8_37_1","first-page":"356","article-title":"Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer","volume":"62","author":"Mohammed SI","year":"2002","journal-title":"Cancer Res."},{"issue":"2","key":"e_1_2_8_38_1","first-page":"906","article-title":"Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma","volume":"9","author":"Henry CJ","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.1996.tb01745.x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122549"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2020.12.029"},{"issue":"2","key":"e_1_2_8_42_1","first-page":"24","article-title":"Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research","volume":"3","author":"Bhatia P","year":"2015","journal-title":"Ann Transl Med."},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7290105"},{"issue":"3","key":"e_1_2_8_44_1","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo YJ","year":"2020","journal-title":"Exp Ther Med."},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071823"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661737"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M212929200"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12309"},{"issue":"7","key":"e_1_2_8_49_1","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug\u2010resistant cancer","volume":"60","author":"Browder T","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1422"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2012.07.015"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1369"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-018-01102-z"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0945-053X(03)00005-2"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01246.2008"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2135406100"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/vru.12339"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601120"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(95)00048-8"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/vru.12652"}],"container-title":["Veterinary and Comparative Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vco.12790","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vco.12790","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vco.12790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T12:29:59Z","timestamp":1692793799000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vco.12790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/vco.12790"],"URL":"https:\/\/doi.org\/10.1111\/vco.12790","archive":["Portico"],"relation":{},"ISSN":["1476-5810","1476-5829"],"issn-type":[{"value":"1476-5810","type":"print"},{"value":"1476-5829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]},"assertion":[{"value":"2021-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}